Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CBIO NASDAQ:GALT NASDAQ:NERV NASDAQ:PCSA NASDAQ:RMTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBIOCrescent Biopharma$13.22-2.1%$0.00$11.06▼$63.00$258.45M1.5227,189 shs11,723 shsGALTGalectin Therapeutics$2.56+4.3%$1.72$0.73▼$3.90$161.71M0.7413,885 shs168,352 shsNERVMinerva Neurosciences$1.69-1.3%$1.67$1.15▼$3.47$11.85M-0.3422,190 shs3,237 shsPCSAHeatwurx$0.22-2.6%$0.26$0.15▼$3.10$2.69M1.35.26 million shs1.53 million shsRMTIRockwell Medical$1.26-2.7%$0.98$0.78▼$5.15$42.89M1.57437,677 shs235,211 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBIOCrescent Biopharma-8.72%-15.04%-98.24%-98.24%-98.24%GALTGalectin Therapeutics+8.89%+13.69%+82.84%+81.48%+4.70%NERVMinerva Neurosciences-2.17%-1.47%-6.94%+15.52%-49.70%PCSAHeatwurx-5.31%+19.12%-33.07%-7.60%-86.56%RMTIRockwell Medical+8.40%+50.35%+25.24%+21.70%-33.16%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBIOCrescent Biopharma3.5142 of 5 stars3.80.00.03.73.21.70.6GALTGalectin Therapeutics1.6086 of 5 stars3.50.00.00.02.41.70.0NERVMinerva Neurosciences4.1381 of 5 stars3.04.00.04.61.90.01.3PCSAHeatwurx3.8366 of 5 stars3.55.00.00.03.31.71.3RMTIRockwell Medical4.1879 of 5 stars3.73.00.04.13.30.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBIOCrescent Biopharma 3.67Strong Buy$25.0085.19% UpsideGALTGalectin Therapeutics 3.00Buy$6.00144.90% UpsideNERVMinerva Neurosciences 2.00Hold$5.00198.51% UpsidePCSAHeatwurx 3.00Buy$2.00769.94% UpsideRMTIRockwell Medical 3.33Buy$4.00210.08% UpsideCurrent Analyst Ratings BreakdownLatest NERV, RMTI, CBIO, PCSA, and GALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025PCSAHeatwurxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $2.006/25/2025CBIOCrescent BiopharmaStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$28.006/20/2025CBIOCrescent BiopharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/18/2025CBIOCrescent BiopharmaLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$22.006/17/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBIOCrescent Biopharma$10K26,392.50N/AN/A$8.24 per share1.64GALTGalectin TherapeuticsN/AN/AN/AN/A($1.68) per shareN/ANERVMinerva NeurosciencesN/AN/A$0.20 per share8.19($3.67) per shareN/APCSAHeatwurxN/AN/AN/AN/A$0.46 per shareN/ARMTIRockwell Medical$97.73M0.45$0.14 per share9.41$1.01 per share1.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBIOCrescent Biopharma-$37.88M-$46.00N/AN/AN/AN/A-293.92%-206.20%N/AGALTGalectin Therapeutics-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/12/2025 (Estimated)NERVMinerva Neurosciences$1.44M$0.822.04N/AN/AN/A-20.68%15.73%8/5/2025 (Estimated)PCSAHeatwurx-$11.85M-$3.08N/AN/AN/AN/A-319.56%-232.40%8/12/2025 (Estimated)RMTIRockwell Medical-$480KN/A0.00N/AN/A-0.27%-0.90%-0.47%8/14/2025 (Estimated)Latest NERV, RMTI, CBIO, PCSA, and GALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025NERVMinerva Neurosciences-$0.95N/AN/AN/AN/AN/A5/15/2025Q1 2025GALTGalectin Therapeutics-$0.20-$0.15+$0.05-$0.15N/AN/A5/13/2025Q1 2025NERVMinerva Neurosciences-$1.07-$0.50+$0.57-$0.50N/AN/A5/12/2025Q1 2025RMTIRockwell Medical-$0.03-$0.04-$0.01-$0.04$17.46 million$18.91 million5/8/2025Q1 2025PCSAHeatwurx-$0.77-$0.30+$0.47-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBIOCrescent BiopharmaN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/APCSAHeatwurxN/AN/AN/AN/AN/ARMTIRockwell MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBIOCrescent BiopharmaN/A2.292.29GALTGalectin TherapeuticsN/A0.080.08NERVMinerva NeurosciencesN/A9.219.21PCSAHeatwurxN/A2.932.93RMTIRockwell Medical0.302.952.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBIOCrescent Biopharma75.19%GALTGalectin Therapeutics11.68%NERVMinerva Neurosciences34.56%PCSAHeatwurx91.93%RMTIRockwell Medical23.31%Insider OwnershipCompanyInsider OwnershipCBIOCrescent Biopharma4.00%GALTGalectin Therapeutics50.10%NERVMinerva Neurosciences8.60%PCSAHeatwurx9.60%RMTIRockwell Medical3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBIOCrescent Biopharma5019.55 million18.77 millionNo DataGALTGalectin Therapeutics963.29 million31.58 millionOptionableNERVMinerva Neurosciences96.99 millionN/ANot OptionablePCSAHeatwurx2011.88 million10.74 millionNot OptionableRMTIRockwell Medical30034.18 million32.95 millionOptionableNERV, RMTI, CBIO, PCSA, and GALT HeadlinesRecent News About These CompaniesRockwell Medical’s Strategic Initiatives and Market Positioning Justify Buy RatingJuly 9 at 6:43 AM | tipranks.comRockwell Medical and Innovative Renal Care Announce Three-Year Partnership Agreement to Ensure Supply Chain Continuity of Quality Hemodialysis ProductsJuly 8 at 7:03 AM | businesswire.comRockwell Medical, Inc. (RMTI) Income Statement - Yahoo FinanceJuly 1, 2025 | finance.yahoo.comRockwell Medical IncJune 24, 2025 | money.usnews.comBuy Rating for Rockwell Medical Amid Growth Potential and Market PositioningMay 19, 2025 | tipranks.comEarnings call transcript: Rockwell Medical Q1 2025 beats EPS forecast, stock jumpsMay 13, 2025 | uk.investing.comRockwell Medical, Inc. (NASDAQ:RMTI) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comQ1 2025 Rockwell Medical Inc Earnings CallMay 13, 2025 | finance.yahoo.comRockwell Medical Inc (RMTI) Q1 2025 Earnings Call Highlights: Navigating Challenges and ...May 13, 2025 | gurufocus.comQ1 2025 Rockwell Medical Inc Earnings Call TranscriptMay 12, 2025 | gurufocus.comRockwell Medical’s Earnings Call: Navigating TransitionMay 12, 2025 | tipranks.comRockwell Medical, Inc. (RMTI) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comRockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2025 | zacks.comRockwell Medical Announces First Quarter 2025 ResultsMay 12, 2025 | businesswire.comRockwell Medical (RMTI) Q1 Revenue Exceeds Expectations Despite Sales DipMay 12, 2025 | gurufocus.comRockwell Medical Announces First Quarter 2025 Results | RMTI Stock NewsMay 12, 2025 | gurufocus.comRockwell Medical Inc Q1 2025 Earnings: EPS of -$0.05 Meets Estimates, Revenue of $18. ...May 12, 2025 | gurufocus.comRockwell Medical, Inc. (NASDAQ:RMTI) Major Shareholder Larson Family Inve Irrevocable Buys 57,000 SharesApril 16, 2025 | insidertrades.comRockwell Medical Investment Trust buys shares worth $94,017April 15, 2025 | investing.comRockwell Medical to Release First Quarter 2025 Results on Monday, May 12, 2025April 14, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNERV, RMTI, CBIO, PCSA, and GALT Company DescriptionsCrescent Biopharma NASDAQ:CBIO$13.22 -0.28 (-2.07%) As of 09:57 AM EasternCrescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.Galectin Therapeutics NASDAQ:GALT$2.56 +0.11 (+4.33%) As of 10:19 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Minerva Neurosciences NASDAQ:NERV$1.69 -0.02 (-1.29%) As of 10:12 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.Heatwurx NASDAQ:PCSA$0.22 -0.01 (-2.57%) As of 10:19 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.Rockwell Medical NASDAQ:RMTI$1.25 -0.04 (-2.71%) As of 10:18 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
